Display options
Cite
Liu C, Mao Z, Yang M, et al. Efficacy and safety of daptomycin for skin and soft tissue infections: a systematic review with trial sequential analysis. Ther Clin Risk Manag. 2016;12:1455-1466doi: 10.2147/TCRM.S115175.
Liu, C., Mao, Z., Yang, M., Kang, H., Liu, H., Pan, L., Hu, J., Luo, J., & Zhou, F. (2016). Efficacy and safety of daptomycin for skin and soft tissue infections: a systematic review with trial sequential analysis. Therapeutics and clinical risk management, 121455-1466. https://doi.org/10.2147/TCRM.S115175
Liu, Chao, et al. "Efficacy and safety of daptomycin for skin and soft tissue infections: a systematic review with trial sequential analysis." Therapeutics and clinical risk management vol. 12 (2016): 1455-1466. doi: https://doi.org/10.2147/TCRM.S115175
Liu C, Mao Z, Yang M, Kang H, Liu H, Pan L, Hu J, Luo J, Zhou F. Efficacy and safety of daptomycin for skin and soft tissue infections: a systematic review with trial sequential analysis. Ther Clin Risk Manag. 2016 Sep 22;12:1455-1466. doi: 10.2147/TCRM.S115175. eCollection 2016. PMID: 27703367; PMCID: PMC5038576.
Copy Download .nbib Format: NLM
Share it on

Ther Clin Risk Manag. 2016 Sep 22;12:1455-1466. doi: 10.2147/TCRM.S115175. eCollection 2016.

Efficacy and safety of daptomycin for skin and soft tissue infections: a systematic review with trial sequential analysis.

Therapeutics and clinical risk management

Chao Liu, Zhi Mao, Mengmeng Yang, Hongjun Kang, Hui Liu, Liang Pan, Jie Hu, Jun Luo, Feihu Zhou

Affiliations

  1. Department of Surgical Intensive Care Unit, Chinese People's Liberation Army General Hospital, Beijing.
  2. Department of Surgical Intensive Care Unit, Xuanhan People's Hospital, Sichuan, People's Republic of China.

PMID: 27703367 PMCID: PMC5038576 DOI: 10.2147/TCRM.S115175

Abstract

BACKGROUND: Skin and soft tissue infections (SSTIs) are significant indications for antibiotic treatment. Daptomycin, a novel antibiotic, has been registered and licensed to be used in the treatment of these infections. However, its efficacy and safety remain controversial.

OBJECTIVE: The objective of this study was to conduct a systematic review with trial sequential analysis (TSA) to evaluate the efficacy and safety of daptomycin for the treatment of SSTIs and to analyze whether the available sample size has been large enough and is conclusive.

METHODS: PubMed, the Cochrane Library, and EMBASE were searched for published randomized controlled trials (RCTs) that compared daptomycin with other antibiotics in adult patients with SSTIs up to February 2016.

RESULTS: This meta-analysis included eight randomized controlled trials (n=2,002). There was no difference in either the clinical success rate (intention-to-treat population: relative risk [RR] =1.04, 95% confidence interval [CI] =0.99-1.10,

CONCLUSION: Daptomycin and comparator drugs are equally efficacious with regard to clinical and microbiological success for patients with SSTIs, and TSA showed that no additional randomized controlled trials are required. Although daptomycin is a good alternative when other antibiotics are contraindicated for patients with SSTIs and it can serve as a first-line treatment for SSTIs, clinicians should be aware of potential adverse events, such as daptomycin-induced acute eosinophilic pneumonia and creatine phosphokinase, when treating patients with daptomycin.

Keywords: daptomycin; meta-analysis; skin and soft tissue infections; trial sequential analysis; vancomycin

References

  1. Curr Opin Infect Dis. 2014 Apr;27(2):146-54 - PubMed
  2. BMC Infect Dis. 2015 Nov 07;15:503 - PubMed
  3. Clin Infect Dis. 2008 Jun 1;46(11):1683-93 - PubMed
  4. J Emerg Med. 2015 Dec;49(6):928-36 - PubMed
  5. BMC Med Res Methodol. 2009 Dec 30;9:86 - PubMed
  6. Antimicrob Agents Chemother. 2000 Nov;44(11):2948-53 - PubMed
  7. Int J Antimicrob Agents. 2013 May;41(5):426-33 - PubMed
  8. BMJ Open. 2014 Jun 24;4(6):e004744 - PubMed
  9. J Clin Epidemiol. 2011 Apr;64(4):380-2 - PubMed
  10. Med Mal Infect. 2016 May;46(3):166-8 - PubMed
  11. Clin Microbiol Rev. 2013 Oct;26(4):759-80 - PubMed
  12. Drugs Aging. 2013 Oct;30(10):829-36 - PubMed
  13. Clin Infect Dis. 2004 Jun 15;38(12):1673-81 - PubMed
  14. Cochrane Database Syst Rev. 2013 Jul 12;(7):CD008056 - PubMed
  15. Int J Clin Pract. 2009 Mar;63(3):368-75 - PubMed
  16. Curr Opin Infect Dis. 2015 Apr;28(2):117-24 - PubMed
  17. BMJ. 2003 Sep 6;327(7414):557-60 - PubMed
  18. Int J Antimicrob Agents. 2012 Jan;39(1):90-1 - PubMed
  19. J Infect Chemother. 2013 Jun;19(3):447-55 - PubMed
  20. Ann Intern Med. 2009 Aug 18;151(4):264-9, W64 - PubMed
  21. Clin Microbiol Infect. 2013 Sep;19(9):E377-85 - PubMed
  22. Clin Microbiol Infect. 2006 Mar;12 Suppl 1:24-32 - PubMed
  23. J Clin Epidemiol. 2008 Aug;61(8):763-9 - PubMed
  24. Curr Med Res Opin. 2015 Aug;31(8):1539-51 - PubMed
  25. J Infect Dis. 2005 Jun 15;191(12):2149-52 - PubMed
  26. J Antimicrob Chemother. 2014 Dec;69(12):3181-9 - PubMed
  27. Antimicrob Agents Chemother. 2003 Aug;47(8):2538-44 - PubMed
  28. Int J Epidemiol. 2009 Feb;38(1):276-86 - PubMed
  29. Int J Clin Pract. 2008 Sep;62(9):1455-64 - PubMed
  30. BMC Infect Dis. 2014 May 23;14:289 - PubMed
  31. J Antimicrob Chemother. 2014 Apr;69(4):1119-26 - PubMed
  32. Stat Med. 2011 Apr 30;30(9):903-21 - PubMed
  33. Ann Pharmacother. 2010 Jan;44(1):97-106 - PubMed

Publication Types